Literature DB >> 8546743

The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources.

M F Cotch1, G S Hoffman, D E Yerg, G I Kaufman, P Targonski, R A Kaslow.   

Abstract

OBJECTIVE: To estimate the prevalence, annual mortality, and geographic distribution of Wegener's granulomatosis.
METHODS: Analysis of national vital statistics data and hospitalization data from a national survey and from all New York State inpatient facilities.
RESULTS: Between 1979 and 1988, 1,784 death certificates in the United States listed Wegener's granulomatosis as a cause of death. Nationally, an estimated 10,771 hospitalizations included Wegener's granulomatosis among the discharge diagnoses. In New York State, there were 978 hospitalizations among 571 individuals with Wegener's granulomatosis.
CONCLUSION: The prevalence of Wegener's granulomatosis in the United States is approximately 3.0 per 100,000 persons. Clear differences in the geographic distribution of Wegener's granulomatosis are apparent when analysis consider rates of disease in individual counties. Contrary to previous reports, associations between disease exacerbations and season were not apparent.

Entities:  

Mesh:

Year:  1996        PMID: 8546743     DOI: 10.1002/art.1780390112

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  51 in total

Review 1.  Rare diseases.3: Wegener's granulomatosis.

Authors:  C A Langford; G S Hoffman
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

2.  Systemic vasculitis: epidemiology, classification and environmental factors.

Authors:  D G Scott; R A Watts
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

3.  Wegener's granulomatosis diagnosed by testicular biopsy.

Authors:  Mahendra Agraharkar; Sumita Gokhale; Rajiv Gupta
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

Review 4.  Nasal manifestations of systemic illnesses.

Authors:  Isam Alobid; Jose Maria Guilemany; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2004-05       Impact factor: 4.806

Review 5.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 6.  Granulomatosis with polyangiitis in childhood.

Authors:  Marinka Twilt; Susanne Benseler; David Cabral
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

Review 7.  Pulmonary vasculitis.

Authors:  Kevin K Brown
Journal:  Proc Am Thorac Soc       Date:  2006

Review 8.  Neutrophil proteinase 3 and dipeptidyl peptidase I (cathepsin C) as pharmacological targets in granulomatosis with polyangiitis (Wegener granulomatosis).

Authors:  Brice Korkmaz; Adam Lesner; Stephanie Letast; Yassir K Mahdi; Marie-Lise Jourdan; Sandrine Dallet-Choisy; Sylvain Marchand-Adam; Christine Kellenberger; Marie-Claude Viaud-Massuard; Dieter E Jenne; Francis Gauthier
Journal:  Semin Immunopathol       Date:  2013-02-06       Impact factor: 9.623

9.  Prognostic factors for hospital mortality and ICU admission in patients with ANCA-related pulmonary vasculitis.

Authors:  Fernando Holguin; Bassel Ramadan; Anthony A Gal; Jesse Roman
Journal:  Am J Med Sci       Date:  2008-10       Impact factor: 2.378

Review 10.  The contribution of genetic variation and infection to the pathogenesis of ANCA-associated systemic vasculitis.

Authors:  Lisa C Willcocks; Paul A Lyons; Andrew J Rees; Kenneth G C Smith
Journal:  Arthritis Res Ther       Date:  2010-02-15       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.